- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01193855
Dutasteride in Treating Patients With Prostate Cancer
Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) With Lower Risk Prostate Cancer Suitable for Active Surveillance. (MAPPED TRIAL)
RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This randomized phase II trial is studying how well giving dutasteride works in treating patients with prostate cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To evaluate the change in volume of foci of prostate cancer as assessed by T2-weighted MRI, following exposure to dutasteride (Avodart) 0.5 mg daily for six months.
Secondary
- To determine the change in volume of prostate cancer as determined by gadolinium-enhanced MRI and diffusion-weighted MRI after 6 months of dutasteride 0.5 mg compared to placebo.
- To determine the change in volume of prostate cancer as determined by T2-weighted MRI, gadolinium-enhanced MRI, and diffusion-weighted MRI after 3 months of dutasteride compared to placebo.
- To determine the changes in MR characteristics of prostate cancer (perfusion, cell density) between baseline and six months in patients on dutasteride compared to placebo.
- To determine the change in volume of prostate cancer as assessed by HistoScan transrectal ultrasound between baseline and six months, in patients on dutasteride compared to placebo.
- To determine the association between the measured prostate cancer volumes on MRI with the measured prostate cancer volumes on HistoScan at baseline and six months in patients on dutasteride compared to placebo.
- To determine the association between the measured changes in prostate cancer volume using MRI, and the measured changes in prostate cancer volume using HistoScan transrectal ultrasound, at baseline and at six months, in patients on dutasteride compared to placebo.
- To correlate changes in tumor volume and characteristics seen on MRI with changes seen on HistoScan between baseline and six months in patients on dutasteride compared to placebo.
- To correlate change in tumor volume and characteristics seen on MRI with histological features as seen on 6-month biopsy (Gleason score and sum, number of cores involved, cancer core length) in patients on dutasteride compared to placebo.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral dutasteride once daily for 6 months. Treatment continues in the absence of unacceptable toxicity.
- Arm II: Patients receive oral placebo once daily for 6 months. Treatment continues in the absence of unacceptable toxicity.
Patients undergo a multi-sequence MRI at baseline, 3 months, and 6 months and HistoScan transrectal ultrasound at baseline and 6 months. Patients may also undergo a targeted biopsy of the prostate (standard transrectal biopsy plus ultrasound-guided targeting of lesions seen on MRI) at 6 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
England
-
London, England, United Kingdom, W1T 7NF
- Recruiting
- University College of London Hospitals
-
Contact:
- Contact Person
- Phone Number: 44-207-380-9194
- Email: markemberton1@btinternet.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed prostate cancer, meeting all of the following criteria:
- Prostate-specific antigen (PSA) < 10.0 ng/mL
- T1c-T2a disease
- Gleason sum of 6 or 7 (secondary pattern 4 only)
Patients with low risk disease must meet the following criteria:
- Gleason pattern 3 + 3
- PSA < 10.0 ng/mL
- Clinical T2a disease
- Patients with Gleason secondary pattern 4 (i.e., Gleason Pattern 3 + 4) are eligible but must not have a primary pattern 4, PSA > 10 ng/mL, or clinical T2b disease
- Measurable disease on MRI of at least 0.2 cc, based on planimetry volume
Biopsy-proven disease within 2 years of screening visit
- No biopsy artifact on MRI scan (minimum 12-week interval between biopsy and baseline MRI)
- Eligible for active surveillance according to the criteria set out by the National Institute for Health and Clinical Excellence
PATIENT CHARACTERISTICS:
- ALT and AST ≤ 2 times the upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2 times ULN
- Bilirubin ≤ 1.5 times ULN
- Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min
- Able to swallow and retain oral medication
- Able and willing to participate in the study for its duration
- Able to read and write (health-outcomes questionnaires are written)
- Able to understand instructions related to study procedures and give written informed consent
- No history of another malignancy within five years that could affect the diagnosis of prostate cancer
- No history or current evidence of drug or alcohol abuse within the last 12 months that might confound the results of the study or pose additional risk to the patient
- No known hypersensitivity to any 5α-reductase inhibitor or to any drug chemically related to dutasteride
No contraindication for undergoing gadolinium-enhanced MRI, including any of the following:
- Inability to see tumor focus of ≥ 0.2 cc on T2 sequences
- Previous allergic reaction to gadolinium
- Serum creatinine > ULN
- Incompatible pacemaker
- Metal fragments in eyes
- Hip replacements that give artifact with prostate/pelvis views
- Any artifact or condition that reduces image quality of MRI (e.g., inability to keep still)
No unstable serious co-existing medical condition(s) including, but not limited, to any of the following:
- Myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening visit
- Uncontrolled diabetes
- Peptic ulcer disease uncontrolled by medical management
PRIOR CONCURRENT THERAPY:
- No prior radiotherapy (external-beam or brachytherapy), high-intensity focused ultrasound (HIFU), or photodynamic therapy (PDT)
- No prior chemotherapy
- At least 3 months since prior and no concurrent prostatic surgery, including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation
No prior oral glucocorticoids
- Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one
- No prior GnRH analogues (e.g., leuprolide, goserelin)
- No prior or concurrent hormonal treatment (e.g., megestrol, medroxyprogesterone, cyproterone, DES) of prostate cancer
No current and/or prior use of the following medications:
- Finasteride (Proscar, Propecia), or dutasteride (GI198745, AVODART) exposure within 12 months prior to study entry
- Any other investigational 5α-reductase inhibitors within the past 12 months
- Anabolic steroids within the past 6 months
Drugs with antiandrogenic properties within the past 6 months (e.g., spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents)
- The use of cimetidine is permitted prior to study entry
- The use of topical ketoconazole is permitted prior to and during the study
- No participation in another investigational or marketed drug trial within the 30 days prior to the first dose of study drug or anytime during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The change in volume of foci of prostate cancer (PC) as assessed by T2-weighted (T2w) MRI between baseline and 6 months
|
Secondary Outcome Measures
Outcome Measure |
---|
The change in volume of PC as determined by gadolinium-enhanced (GE) MRI and diffusion-weighted (DW) MRI at 6 months
|
The change in volume of PC as determined by T2w MRI, GE MRI, and DW MRI at 3 months
|
The changes in MR characteristics of PC (perfusion, cell density) between baseline and 6 months
|
The change in volume of PC as assessed by HistoScan transrectal ultrasound (TRUS) between baseline and 6 months
|
The association between the measured PC volumes on MRI with the measured PC volumes on TRUS at baseline and 6 months
|
The association between the measured changes in PC volume using MRI vs TRUS at baseline and 6 months
|
The association of PC volume change with qualitative changes seen on TRUS between baseline and 6 months
|
The association between MR changes in volume and characteristics with histological features as seen on 6-month biopsy (Gleason score and sum, number of cores involved, cancer core length)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mark Emberton, MD, FRCS, MBBS, University College London Hospitals
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- 5-alpha Reductase Inhibitors
- Dutasteride
Other Study ID Numbers
- CDR0000684018
- UCL-09-0221
- EUDRACT-2009-012405-18
- EU-21067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on diffusion-weighted magnetic resonance imaging
-
Ohio State University Comprehensive Cancer CenterWithdrawn
-
Jonsson Comprehensive Cancer CenterU.S. Army Medical Research and Development Command; U.S. Army Medical Research...CompletedBreast Carcinoma | Malignant Breast Neoplasm | Benign Breast NeoplasmUnited States
-
Medical University of ViennaMedical University InnsbruckWithdrawnStroke, Acute
-
Bezmialem Vakif UniversityCompletedGastric AdenocarcinomaTurkey
-
Assiut UniversityUnknown
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); University of Iowa; Oregon Health and Science... and other collaboratorsRecruiting
-
Chinese University of Hong KongActive, not recruitingMultiple SclerosisHong Kong
-
Washington University School of MedicineTerminatedSquamous Cell CarcinomaUnited States
-
Laval UniversityRecruitingPancreas Adenocarcinoma | Pancreas Cancer, Duct Cell Adenocarcinoma | Peritoneal Carcinomatosis | Peritoneal MetastasesCanada
-
Brugmann University HospitalCompleted